ACUR · As filed with the SEC
Acura Pharmaceuticals income statement, by fiscal year
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|
| Revenues: | ||||
| Royalties | 132,000 | 109,000 | 372,000 | 410,000 |
| Product sales, net | — | — | — | 0 |
| Collaboration from related party | 31,000 | 238,000 | 185,000 | 0 |
| License fees from related party | 1,400,000 | 3,000,000 | 2,100,000 | 0 |
| Product sales | 0 | 223,000 | — | — |
| Total revenues | 1,563,000 | 3,570,000 | 2,657,000 | 410,000 |
| Expenses: | ||||
| Cost of sales | — | — | — | 0 |
| Research and development | 1,524,000 | 1,781,000 | 1,505,000 | 1,759,000 |
| General and administrative | 1,253,000 | 2,547,000 | 1,877,000 | 2,566,000 |
| Total expenses | 2,777,000 | 4,328,000 | 3,382,000 | 4,325,000 |
| Operating loss | (1,214,000) | (758,000) | (725,000) | (3,915,000) |
| Loss on debt extinguishment (Note 7) | — | — | (2,600,000) | 296,000 |
| Total other income (expense), net | — | — | — | 73,000 |
| Gain on forgiveness of a loan under CARES Act | 535,000 | — | — | — |
| Interest expense to related party | (200,000) | (450,000) | (449,000) | (223,000) |
| Loss before provision for income taxes | (879,000) | (1,208,000) | (3,774,000) | (3,842,000) |
| Provision for income taxes | 0 | 0 | 0 | 0 |
| Net loss | (879,000) | (1,208,000) | (3,774,000) | (3,842,000) |
| Net income (loss) per share: | ||||
| Basic | (0.02) | (0.04) | (0.14) | (0.18) |
| Diluted | (0.02) | (0.04) | (0.14) | (0.18) |
| Weighted average number of shares outstanding: | ||||
| Basic | 56,801,000 | 32,320,000 | 26,720,000 | 21,146,000 |
| Diluted | 56,801,000 | 32,320,000 | 26,720,000 | 21,146,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.